Forxiga & Jardiance are expected to surpass 100 billion won

in sales this year

22.1 billion and 30.9 billion, respectively, in the first half of the year

Forxiga, next year's patent expiration price variable

The SGLT-2-inhibited original diabetes treatment market recorded 53 billion won in the first half of this year, which is expected to surpass 100 billion won by the end of this year.

 

The SGLT-2 original drug market was divided into Forxiga and Beringer Ingelheim Jardiance, and sales of 22.1 billion won and 30.9 billion won in the first half, respectively.

 

The total sales of both Forxiga and Jardiance products last year were 91.6 billion won, up 94% from 47.1 billion won in 2018.

 

From 2018 to 2021, Jardiance's sales were 19.8 billion won, 26.1 billion won, 29.4 billion won, and 32.3 billion won.

 

During the same period, Jardiance Duo recorded 2.5 billion, 6.5 billion, 13.8 billion, and 21.1 billion won.

 

Compared to the pace of growth between 2018 and 2021, Jardiance Duo increased by 63% (19.8 billion → 32.3 billion) and 744% (2.5 billion → 21.1 billion).

 

Jardiance Duo's overall sales last year were 53.4 billion won, 15.3 billion more than Posh's 38.1 billion won.

 

Jardiance Duo's sales in the first half of this year were 17.5 billion won and 13.3 billion won, respectively, and if such an elastic curve is maintained, it is expected to grow by 8.26% compared to the previous year.

 

Forxiga's growth rate over the past four years is 54%, and its appearance between 2018 and 2021 recorded 24.7 billion won, 27.9 billion won, 32 billion won, and 38.1 billion won.

 

Forxiga 10mg, which was approved in Korea in 2013, maintained 784 won at the beginning of its launch but was cut by 24 won to 760 won in May this year.

 

This drug is used in type 2 diabetes monotherapy and is effective in reducing the risk of chronic heart failure and chronic kidney disease hospitalization and death.

 

In particular, Forxiga is expected to compete fiercely in the market between original and generic due to the expiration of material patents in the first half of next year.

 

When the patent expires, the original drug Forxiga will be recognized for 70% (532 won) of the existing drug price, 68% (516 won) of the generic released by innovative pharmaceutical companies, and 59.5% (452 won) of the generic.

 

Jardiance, which was approved in 2014, is also used as a single and combination therapy for blood sugar control in type 2 diabetic patients, just like Forxiga.

 

Jardiance 10 and Jardiance 25mg prices are 660 won and 852 won, respectively.

 

Jardiance Duo 5/500, 5/850, 5/1000, 12.5/500, 12.5/850, and 12.5/1000 mg receive insurance drug prices of around 330 won to 469 won.

 

New diabetes drugs with SGLT-2 inhibition mechanism have advantages of more advanced efficacy and low side effects, such as less strain on the kidneys while showing excellent blood sugar drop effects compared to existing treatments.